Clinical Trials Browser

Not yet recruiting × Neoplasm, Residual × Clear all

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT07392970 2026-02-06

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Not yet recruiting

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting

Prostatic Neoplasms, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07247201 2025-12-09

AlloNK1

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07269067 2025-12-08

DUALFLOW

Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

Phase 2 Not yet recruiting

Neoplasm, Residual

NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

Not yet recruiting

Multiple Myeloma, Neoplasm, Residual

NCT06941987 2025-04-24

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

Not yet recruiting

Neoplasm, Residual

NCT06854939 2025-03-03

MRDSEEKER

Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT06763302 2025-01-08

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

Phase NA Not yet recruiting

Neoplasm, Residual

NCT06449846 2024-06-10

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence, Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Phase NA Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

Lung Neoplasms, Neoplasm, Residual

NCT06287723 2024-03-01

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Not yet recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT05850377 2023-05-09

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Not yet recruiting

Brain Neoplasms, Glioma, Neoplasms, Central Nervous System Neoplasms, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Neoplasm, Residual